American Diversified Holdings Updates on GlucoGuard Project Progress

American Diversified Holdings Corporation (ADHC) has announced significant advancements in the development of its innovative GlucoGuard system, following a detailed update from its partner, Arete Biosciences, Inc. The San Diego-based bioengineering firm has made substantial progress on various fronts, including a thorough review of engineering schematics and relevant patent filings, as well as the integration of recommendations from the Food and Drug Administration (FDA).

The Arete engineering team has established a comprehensive computer-aided design (CAD) plan for the next development phase. This phase consists of several key objectives: finalizing the product design based on updated requirements, creating a prototype for usability studies, and providing an estimated budget for this upcoming phase. The usability study will include approximately ten participants to assess the device’s wearability and comfort, as mandated by the FDA. Arete anticipates completing this stage within the next 7 to 10 days.

Collaboration with Experts and Future Steps

The team at Arete Biosciences has conducted an extensive review of GlucoGuard’s foundational documentation, which includes intellectual property, design schematics, and FDA application documentation. A development protocol has been devised with input from GlucoGuard’s advisor, Dr. Stephen Weber, who serves as an Assistant Professor at the Johns Hopkins School of Medicine. Dr. Weber previously held a position as a Medical Officer and Clinical Reviewer at the FDA and has over 25 years of experience as an orthopedic surgeon. His involvement will facilitate the next steps in the FDA approval process.

Further developments regarding the partnership with DEXCOM, advancements in using artificial intelligence to predict hypoglycemia, and other critical updates will be communicated in the near future.

About GlucoGuard and Market Potential

GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system, aims to prevent dangerous hypoglycemic episodes during sleep, including the life-threatening “Death in Bed” phenomenon. This innovative device is at the forefront of diabetes management technology, developed in collaboration with a leading U.S. research university, a prominent biomedical engineering firm, and a major continuous glucose monitoring (CGM) company.

The system employs advanced engineering, artificial intelligence, and mobile app-based monitoring to create a comprehensive solution for managing nocturnal hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected, allowing for effective glucose management without disturbing the patient’s rest.

The diabetes market is poised for substantial growth, with the U.S. market valued at $28 billion, highlighting the potential for GlucoGuard’s adoption. The Continuous Glucose Monitoring sector alone is valued at $6.8 billion, underscoring the critical demand for innovative glucose management solutions.

For further information about GlucoGuard, visit www.GlucoGuardSleep.com or contact John Cacchioli, CEO of American Diversified Holdings Corporation, at 212-537-5900 or via email at [email protected].

The announcement also includes a safe harbor clause regarding forward-looking statements, cautioning that actual results may differ from projections due to various risks and uncertainties. These risks are detailed in the company’s filings with the U.S. Securities and Exchange Commission (SEC) and other regulatory bodies.

In conclusion, the progress made by Arete Biosciences and the continuing development of GlucoGuard signify important steps toward enhancing diabetes management solutions, potentially benefiting patients worldwide.